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HIV-1 usurps the RNA polymerase II elongation control machinery to regulate the expression of its genome during lytic and
latent viral stages. After integration into the host genome, the HIV promoter within the long terminal repeat (LTR) is subject to
potent downregulation in a postinitiation step of transcription. Once produced, the viral protein Tat commandeers the positive
transcription elongation factor, P-TEFb, and brings it to the engaged RNA polymerase II (Pol II), leading to the production of
viral proteins and genomic RNA. HIV can also enter a latent phase during which factors that regulate Pol II elongation may play a
role in keeping the virus silent. HIV, the causative agent of AIDS, is a worldwide health concern. It is hoped that knowledge of the
mechanisms regulating the expression of the HIV genome will lead to treatments and ultimately a cure.
1.Introduction
According to the 2010 UNAIDS AIDS Epidemic Update,
over 33 million people live with human immunodeﬁciency
virus (HIV) type 1, a number that is increasing due to a
combination of improved treatment and continued trans-
mission. Upon crossing the mucosa, HIV docks with CD4+
cells such as T-lymphocytes and macrophages, fuses with
the host cell, and releases viral single-stranded RNA, reverse
transcriptase, and integrase into the cytoplasm. Reverse
transcriptase converts the HIV RNA into double-stranded
DNA, at which point integrase chaperones the viral DNA
into the nucleus for integration into the host genome. An
initialroundofhost-inducedgeneexpressionbyPolIIresults
in expression of Tat, the primary transactivator of HIV,
which then recruits the positive transcription elongation
factor P-TEFb containing Cdk9 and Cyclin T1 to the HIV
LTR [1, 2]. This leads to increased viral gene expression
and, eventually, replication of the HIV genome, assembly
into new viral particles, and budding. HIV is capable of
establishing life-long latent infection by suppressing its
transcription, thus evading current antiretroviral therapies
[3]. How HIV subverts Pol II elongation control during both
active and latent infections has received a signiﬁcant amount
ofattention,anditishopedthattheseinquireswillleadtothe
development of more eﬀective treatments and an eventual
cure.
Regulation of transcription of many human genes is
accomplished by a process termed RNA polymerase II
elongation control, and, after integration, the HIV LTR falls
under this control. In fact, the HIV LTR has been used
as a model to study the regulation of transcription at the
level of elongation. In general, most human genes experience
initiation, but the fraction of those initiation events that
result in mRNAs is tightly regulated. After initiation, Pol II
is directed by negative elongation factors that include DSIF
and NELF to pause after synthesizing approximately 30–100
nucleotides of RNA [4]. These promoter proximally paused
polymerases either prematurely terminate, or enter pro-
ductive elongation under the inﬂuence of P-TEFb, thereby
generating mRNAs or in the case of HIV, viral genomes [5].
Because of its important role in this process, the activity
of P-TEFb is restricted by reversible association with 7SK
snRNA-bound HEXIM1 or HEXIM2 proteins which inhibit
the kinase activity of P-TEFb during its residence within
the 7SK snRNP [6, 7]. A number of cellular activators2 Genetics Research International
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Figure 1: Early rounds of HIV transcription. At the HIV LTR, TATA-binding protein (TBP) is recruited to the TATA box with the aid of
Sp1. This interaction is subsequently stabilized by TFIIA and TFIIB. Preinitiation complex assembly is completed by the sequential addition
of Pol II•TFIIF, TFIIE, and TFIIH and is followed by promoter clearance. Pol II quickly falls under the negative inﬂuence of DSIF and
NELF, pausing after the generation of a short, nascent transcript. The recruitment of P-TEFb through NFκB or other factors overcomes this
inhibition by phosphorylating DSIF and NELF, allowing for productive elongation and the generation of HIV Tat.
including Brd4 [8, 9], c-Myc [10–12], NFκB[ 13], and others
interact with and recruit P-TEFb to overcome this hurdle
to transcription [14]. Recent ChIP-Seq experiments have
revealed that promoter proximally paused polymerases are
a prominent feature of chromatin [10] highlighting the
relevance of elongation control to human transcription and
disease. A growing body of evidence suggests that not only
is HIV regulated by elongation control, but that the virus
manipulates the machinery that regulates P-TEFb for the
purposes of viral gene expression, replication, and latency.
2. The FirstStepsof HIVGeneExpression
The HIV LTR region is composed of several redundant
elements that promote the swift and spontaneous assembly
of the preinitiation complex (PIC) [15] (Figure 1). While
most eukaryotic core promoters contain either a TATA box
or a pyrimidine-rich initiator region, HIV plays host to
both elements, encouraging the recruitment of transcription
factors. Three tandem-repeat speciﬁcity protein 1 (Sp1) sites
further promote PIC assembly and are indispensible in HIV
transcription [16]. Sp1 stimulates the recruitment of TATA-
binding protein (TBP), a subunit of TFIID, to the TATA
box; this interaction is immediately stabilized by TFIIA and
TFIIB (Figure 1, ﬁrst panel). The subsequent assembly of
Pol II•TFIIF, TFIIE, and TFIIH completes the formation of
the PIC, allowing for initiation and promoter clearance [17]
(Figure 1, second panel). In terms of initiation eﬃciency the
HIV LTR is one of the strongest promoters known.
Immediately following initiation in the 5  LTR, Pol II
falls under the inﬂuence of negative elongation factors that
include DSIF and NELF [18], pauses, and produces only
short transcripts [19] (Figure 1, third panel). NELF has been
shown to interact directly with the HIV nascent transcript
TAR to inhibit elongation [20]. DSIF and NELF further
encouragetheformationofpoisedpolymerasesbyinhibiting
transcript cleavage factor TFIIS [21], but this factor may be
needed ultimately to restart elongation [22]. In contrast to
the highly eﬃcient initiation that takes place on the LTR,
the escape of promoter proximally paused polymerases into
productive elongation is very ineﬃcient. This is due to a
combination of the strong interaction of NELF with the
nascent HIV transcript [20] and potentially to the aﬃnity of
HEXIM proteins to thesameRNAstructure[23].Due tothis
strong negative inhibition, HIV is incapable of productive
elongation without elevated levels of P-TEFb. The reduction
of available P-TEFb through inhibitors or expression of
kinase dead Cdk9 mutant blocks HIV gene expression while
leaving overall cellular transcription relatively unaﬀected
[24–27]. HIV achieves its initial rounds of productiveGenetics Research International 3
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Figure 2: Structural detail of Tat•P-TEFb interaction. The two panels depict surface (upper) and cartoon (lower) representations of the
crystal structure of the complex between HIV Tat and P-TEFb. Tat is full length 86 amino acid protein, but only residues 1–49 are visible.
Cdk9 (dark green) is a 1-345 truncation of the 372 amino acid protein. Cyclin T1 (light green) is a 1–266 truncation of the 726 amino acid
protein. The two zinc atoms coordinated by the interface of Tat and cyclin T1 are indicated as yellow spheres. ATP (magenta) and Mg (blue)
are shown bound to the active site of Cdk9. The ﬁgure was created using Pymol from PDB entry 3MIA [34].
elongation through lymphocyte cellular activation, which
increases Cyclin T1 expression and P-TEFb activity to levels
suﬃcient for HIV gene expression [28].
T-cell activation triggers the activity of transcription
factor NFκB, composed of subunits p50 and p65 (RelA),
and NFAT. In response to a wide range of stimuli including
TNF-α,N F κB inhibitor IκB becomes phosphorylated and
subsequently degraded, allowing NFκB to translocate into
the nucleus and localize to genomic binding sites [29],
where the p65 subunit can be found in association with P-
TEFb [13]. Two NFκB sites in close proximity to the Sp1
binding elements in the HIV LTR are shown to strongly
enhance HIV transcription [30]; synergy between the p65
subunit and Sp1 further augments the shift from abortive to
productive elongation in HIV [30] (Figure 1,f o u r t hp a n e l ) .
Two additional sites downstream of the transcription start
site also enhance HIV’s transcriptional sensitivity to NFκB
[31], though their role is less well understood. The nuclear
factor of activated T cells, NFAT, likely plays a similar role
[32] binding as a dimer to the same DNA binding elements
[33]. These sites allow for the recruitment of enough P-
TEFb to the HIV LTR to phosphorylate DSIF and NELF and
trigger at least some poised polymerases to enter productive
elongation, and this results in the production of Tat and the
entry into the second phase of HIV transcription [13].
3. Maintenanceof Highly EfﬁcientHIV Gene
Expressionand ViralReplication
During the next stage of HIV infection an extremely high
level of transcription of the viral genome is directed by Tat,
the major transactivator of HIV transcription. Tat is an HIV
protein designed for direct interaction with P-TEFb, mainly
with Cyclin T1, but also with Cdk9 [1, 2, 24, 34]. Tat is
required for eﬃcient productive elongation of HIV genes
[1, 19, 35, 36], and this stimulatory eﬀect depends on P-
TEFb[24–27].Tat’sabilitytointeractwithP-TEFb(Figure2)
allows it to extract the kinase from the 7SK snRNP and bring
it to poised polymerases on the LTR (Figure 3). This activates
HIV transcription by exploiting the ability of P-TEFb to
stimulate productive elongation of HIV-bound polymerases,
allowing for eﬀective viral gene expression and replication.
X-raycrystallographyhasprovenusefulinclarifyingTat’s
association with P-TEFb (Figure 2). Tat lacks a prominent
secondary structure when free in solution, but upon inter-
acting with P-TEFb, peptides 1–49 become highly organized4 Genetics Research International
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Figure 3: Tat overrides cellular elongation control. Tat interacts directly with P-TEFb sequestered in the 7SK snRNP. This results in a
conformational change of 7SK, ejecting HEXIM proteins, and preventing P-TEFb•HEXIM1•7SK reassembly. Tat•P-TEFb migrates to
the TAR element contained within HIV’s nascent transcript, binds, and acts upon DSIF and NELF, eﬃciently overcoming inhibition of
transcription.
and form a structure complimentary to the kinase [34]. Tat
interacts primarily with Cyclin T1, using 88% of its surface
area and a Zn-mediated bridge to stabilize the interface
[34]. Tat also inserts into a groove between Cyclin T1
and Cdk9, resulting in a more stable and active P-TEFb
kinase [34]. While comparisons of Tat•P-TEFb•ATP to a
previous P-TEFb•ATP structure [37] suggested Tat altered
theconformationofP-TEFb,itispossiblethatthediﬀerences
in structures were due to 3 amino acid substitutions in the P-
TEFb•ATP crystal, one of which lies in the critical surface
between Cdk9 and Cyclin T1. What is clear is that Tat binds
speciﬁcally to Cyclin T1 and forms a very stable complex.
In fact, when Tat is overexpressed in HeLa cells, greater
than 90%, of the Tat is found associated with P-TEFb [23].
Evidently excess Tat is degraded.
Tat’s most striking behavior is its ability to recruit
sequestered P-TEFb from the 7SK snRNP (Figure 3,t o p ) ,
subverting cellular elongation control, and guaranteeing
a supply of P-TEFb for HIV replication. When P-TEFb
inhibitors were titrated onto cells, a gradual decrease in
the ratio of P-TEFb in the 7SK snRNP to free P-TEFb was
observed and the IC50 for that change is identical to the
IC50 for inhibition of HIV replication [27]. This and other
experiments suggest that the 7SK snRNP is required for HIV
replication. Importantly, HIV infection or expression of Tat
in HeLa cells results in the release of P-TEFb from the 7SK
snRNP [23, 38]. Under the later conditions the majority of
the Tat is found in a Tat•P-TEFb complex that sediments in
a glycerol gradient with signiﬁcantly lower molecular weight
than the 7SK snRNP [23]. Using a deﬁned in vitro assay in
which the 7SK snRNP was immunoprecipitated from HeLa
cell lysates, recombinant Tat was able to extract P-TEFb
directly and this release was completely dependent on the
P-TEFb binding domain of Tat [8]. In the presence of Tat,
cellular control of P-TEFb via the 7SK snRNP is no longer
eﬀective at limiting HIV transcription.
In addition to Tat being able to bind to and extract P-
TEFb from the 7SK snRNP, it also can interact with 7SK
directly. Electrophoretic mobility shift assays demonstrated
that Tat could bind to 7SK RNA in a dose-dependent
manner and that this interaction displaced HEXIM1 and
prevented P-TEFb•HEXIM1•7SK reformation at increasing
Tat concentrations [23]. The role for binding of Tat to 7SK
snRNA is not clear. Although the P-TEFb binding domain
of Tat was indispensible for extraction of P-TEFb from the
7SK snRNP, the RNA binding domain only had a slight
stimulatory eﬀect [8]. Another study provided evidence
for Tat association with 7SK snRNP that lacked HEXIM1
[39]. Reconciliation of all of these results may be achieved
by taking into consideration that 7SK snRNA undergoes a
conformational change upon loss of P-TEFb [8] (Figure 3,
topright).Chemicalprotectionexperimentsprovidedstrong
evidence for this conformational change in 7SK RNA after
loss of P-TEFb due to ﬂavopiridol treatment of cells orGenetics Research International 5
after treatment of the 7SK snRNP with recombinant Tat
[8]. It was hypothesized that loss of HEXIM was caused by
the conformational change in 7SK RNA. Binding of Tat to
7SK could also be negatively aﬀected by the restructuring
event. The study that detected Tat bound to the 7SK snRNP
could be explained by the higher aﬃnity of Tat compared to
HEXIM1 for binding to 7SK RNA.
After Tat has extracted P-TEFb from the 7SK snRNP, the
Tat•P-TEFb complex is recruited to the poised polymerase
through an interaction with the transactivation response
element, TAR (Figure 3, bottom). TAR, contained within
HIV’s nascent transcript, has a bulge and loop hairpin
structure which, when combined with its RNA sequence,
is used by Tat•P-TEFb for speciﬁc binding [40]. Due
to the close proximity of P-TEFb kinase targets, Tat•P-
TEFb•TAR eﬃciently phosphorylates DSIF and NELF and
eﬀects productive elongation. Recent studies suggest that
interactions of Tat with other cellular factors may also be
involved. Tagged Tat protein was found to form two distinct
complexes, one containing P-TEFb, PAF1, AF9, ENL, AFF1,
AFF4, ELL, and EAF1 (Tatcom1) and the other containing
P-TEFb, 7SK, LARP7, and MePCE (Tatcom2) [39]. The
superelongation complex [41] with Tat, Tatcom1 was shown
to be more eﬃcient at Pol II CTD phosphorylation than
Tat•P-TEFb alone and may serve to overcome a diverse set
of repressive cellular blocks to HIV replication [39]. While
a role for Tatcom2 was not discovered, concurrent research
demonstrated the presence of a repressive, Tatcom2-like
Tat•P-TEFb•HEXIM1•7SK complex at poised polymerases
before the synthesis of TAR [42]. The generation of TAR
was necessary for Tat-mediated HEXIM1 displacement and
the activation of P-TEFb, potentially explaining the origin
of Tatcom2. It is still not known if P-TEFb•HEXIM1•7SK
without Tat is capable of localizing to the HIV LTR, either
as a part of the PIC or the poised polymerase [43].
Understanding that Tat may participate in both a highly
stimulatory complex (Tatcom1) and a regulatory, inhibitive
complex (Tat•P-TEFb•HEXIM1•7SK) provides a host of
new questions regarding HIV’s use of elongation control.
4. Elongation Control and Viral Latency
Current HIV therapies are extremely eﬀective at reducing
viremia, thereby improving patient health and reducing
viral transmission; however, the persistence of latent viruses
dictates that the antiviral treatments must be continued for
life. Elimination of the latent viral reservoirs is required
to cure a patient. The current idea is that this could be
accomplished by forcing reactivation of latent viruses while
blocking new infections with antivirals [44]. If the activation
is thorough, all latently infected cells would be killed and
the virus would be eliminated from the host. Most of the
latent viruses are found in resting CD4+ T cells, that were
initially infected, but never began to lytically produce virus
[45]. These cells can remain dormant for decades but, upon
activation, can express virus leading to AIDS.
There are multiple mechanisms working to maintain
stably integrated viruses in a latent state. Because most
HIV integration events take place within active genes, tran-
scriptional interference may play a role in latency [46, 47].
This occurs when elongating RNA polymerase II molecules
travel through the HIV promoter, potentially hindering
initiation and polymerase pausing. This mechanism has
been demonstrated using a Jurkat cell model [48, 49], but
the contribution of this mechanism in resting T cells that
have lower levels of transcription in general is not as clear.
One issue contributing to latency is that key factors needed
for production of long HIV transcripts are found in very
low concentrations in resting T cells. These include NFκB
and/or NFAT as well as P-TEFb containing Cyclin T1, and
the nuclear concentrations of these factors are substantially
increased following T-cell activation [28, 29].
Because only 1 in a million resting T cells may harbor
al a t e n tv i r u s ,i ti sv e r yd i ﬃcult to analyze the state of the
integrated genes. Chromatin immunoprecipitation (ChIP)
can provide an indication of the occupancy by speciﬁc
factors, and relative occupancy of a given factor at diﬀerent
sites can be fairly quantitatively assessed if ChIP-Seq is used.
Without a method to enrich latently infected cells, however,
ChIP lacks the sensitivity to obtain signiﬁcant signals from
the integrated viral genomes. Because of this, model systems
using clonal populations of transformed cells from a single
integration event or primary CD4+ cells with heterogeneous
integrations have been developed [50]. The choice of model
system is important because the growth state of the cells
inﬂuences the transcription factor environment.
The design of methods to activate latent viruses is
hampered by the lack of certainty concerning the chromatin
state of the HIV promoter. Two possibilities are a completely
repressed chromatin structure (Figure 4 top) or an open
promoter conﬁguration with a poised polymerase (Figure 4
bottom), and latent cells could be a mixture of both. A
repressive chromatin structure could be actively maintained
by histone deacetylases (HDACs) recruited by factors such
as Sp1 or by a default pathway that covers DNA in the
absence of promoter use [51]. Supporting a role for HDACs
in maintaining HIV latency, HDAC inhibitors have been
demonstrated to activate latent viruses [52]. Evidence also
suggests a signiﬁcant role for open promoter regulation. In
growing cells, ChIP-Seq experiments have revealed that most
mammalian genes are occupied by promoter proximally
paused polymerases including genes that have very low or
undetectable expression [10] .T h eH I VL T Rw a so n eo ft h e
ﬁrst promoters found to generate poised polymerases, and
short, nonpolyadenylated transcripts containing TAR have
been found in latently infected resting T cells [47, 53].
Therefore, it is very likely that the main block to expression
in many latently infected cells may occur at the P-TEFb-
dependent step in the transition into productive elongation.
I fl a t e n tv i r a lg e n o m e sa r el o a d e dw i t hp o i s e dp o l y -
merases, what is blocking the function of P-TEFb? As
described earlier, NFκB can recruit P-TEFb, but, in resting
T cells, NFκB resides mainly in the cytoplasm. Without some
transcription of the HIV genome, the primary recruiter of
P-TEFb, Tat, will be absent. Another possible elongation
repression mechanism was suggested by the ﬁnding that
H E X I M 1c o u l db i n dt oT A R[ 23] (Figure 4,b o t t o m ) .6 Genetics Research International
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Figure 4: Possible mechanisms for maintaining latent viral genomes. The two panels represent two possible chromatin states over the HIV
LTR in resting T cells in which the HIV genome is maintained in a silent state. In the upper panel, the entire LTR is covered in nucleosomes
and initiation from the promoter is completely blocked. A less extreme but similar possibility (not pictured) is that accessibility of some
factors is allowed, but initiation is still blocked. The lower panel depicts a state in which initiation is allowed, but all polymerases are left
promoter proximally paused. HEXIM proteins may associate with TAR and act as a P-TEFb repressor.
The interaction of TAR with HEXIM1 would trigger the
conformational change needed for P-TEFb binding [54] and,
therefore, would act as a P-TEFb repressor [23]. The eﬀects
of reducing or increasing the level of HEXIM1 on expression
from the HIV LTR has been interpreted as being mediated
through the sequestration of P-TEFb by the 7SK snRNP [55–
58]. However, direct binding of HEXIM1 to TAR can explain
this inﬂuence on transcription [23]. It is currently not clear
if HEXIM1 is bound to many nascent transcripts in human
cells or if its interaction with TAR is speciﬁc.
5.Therapeutic ApproachesTargeting
HIVTranscription
The current cadre, of anti-HIV drugs target enzymes
e n c o d e db yt h ev i r u sa n da r eq u i t ee ﬀective until an
HIV strain arises that is resistant. The error-prone nature
of reverse transcriptase and recombination events lead to
frequent mutations in the presence of drug-induced selective
pressure, leading to resistance and proliferation despite
therapy [59–61]. For this reason, most HIV treatments
utilize at least three drugs with diﬀerent targets. There are
no currently available drugs that inhibit HIV transcription.
Because P-TEFb is essential for HIV replication, the strong
P-TEFb inhibitor ﬂavopiridol blocks virus production [26].
Unfortunately, concentrations about 10-fold higher than
those that block HIV replication also cause host cell death
[27]. This is true for all P-TEFb inhibitors tested except for
those that have other essential targets, in which case the
therapeutic index is less than 10 [25, 27].
Because only HIV utilizes the Tat•P-TEFb complex, it
is the logical target for a viral transcriptional inhibitor, and
thereareseveralpossibleavenuestodevelopcompoundsthat
block the function of this complex. A small molecule that
blocked theinteractionbetweenTatandP-TEFbwouldlikely
inhibit HIV transcription. It will be diﬃcult to ﬁnd such a
compound, however, because Tat buries 3,499 ˚ A2 of surface
area when bound to P-TEFb. An additional challenge in the
search for such compounds is Tat’s limited structure in the
absence of P-TEFb. Another constraint to this approach is
that compounds capable of preventing Tat from binding to
CyclinT1orCdk9mightalsoblockbindingofcellularfactors
such as HEXIM1, NFκB, Brd4, or CIITA, potentially causing
unacceptable toxicity.
Another approach is to obstruct the recruitment of
the Tat•P-TEFb complex to TAR. Compounds that block
binding of Tat to TAR in vitro have been discovered [62–65],
but have not been proven to work well in vivo for a variety
of reasons including low aﬃnity, poor uptake into cells, or
other properties that make them inappropriate for delivery
at eﬃcacious concentrations. The Tat•P-TEFb complex has a
higher aﬃnity to TAR than Tat alone, and such a drug would
have to overcome the additional contribution from Cyclin
T1. Despite these setbacks, the potential for well-targeted
drugs using this approach cannot be overlooked.
Finally, inhibition of the kinase activity of the Tat•P-
TEFb complex speciﬁcally could block HIV transcription
without aﬀecting the cellular function of the important
factor.ComparisonofthestructuresofP-TEFbwith[34]and
without[37]TatsuggestedthatTatinducedaconformational
change that could be exploited to develop a speciﬁc Tat•P-
TEFb inhibitor. However, as mentioned above, change may
have been due to mutations in the proteins used in the
P-TEFb alone structure [34]. Solution of the structure ofGenetics Research International 7
wildtype P-TEFb is needed to resolve this issue. It may be
possible to target the kinase activity of Tat•P-TEFb speciﬁ-
callybytetheringaweakkinaseinhibitortoacompoundthat
binds tightly to the complex at the interface between Tat and
P-TEFb. The anchor would provide speciﬁcity and increase
the concentration of the inhibitor to eﬀective levels. This
method would take advantage of the tremendous stability
of the Tat•P-TEFb complex but would require a signiﬁcant
amount of labor to design or discover the anchoring moiety
of the compound.
Toward a cure for HIV, drugs that stimulate the reactiva-
tion of latently infected cells could allow for the subsequent
eradication of the virus using existing antiretroviral treat-
ments. Prostratin, a protein kinase c activator, induces the
NFκB signaling pathway and stimulates HIV gene expression
in latently infected cells without causing cell replication [66],
but fails to uniformly activate latent cell populations [67].
Further, high-dose or prolonged treatments with prostratin
wereshowntoinducegrowtharrestandcelldeath,hindering
its use as a therapeutic [67]. If HEXIM proteins are found
to be important in maintaining latency as described above,
reactivation and subsequent elimination of the virus may
also be possible by speciﬁcally relieving this block. For
this approach to work, the mechanism must be unique
to the HIV LTR or the HEXIM1•TAR interaction would
have to be targeted speciﬁcally. Care would be needed
to avoid disrupting the interaction of HEXIM with the
7SK snRNP. Structural information about the HEXIM•P-
TEFb•TAR complex is needed to further deﬁne the function
of HEXIM proteins on the LTR.
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